Current situation of lipoprotein apheresis in Saxony

Atherosclerosis Supplements

Volumn 14, Issue 1, 2013, Pages 51-55

  Julius, U ^a   Taseva, K ^a   Fischer, S ^a   Passauer, J ^a   Bornstein, S R ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Cardiovascular diseases; High atherogenic risk; LDL cholesterol; Lipoprotein apheresis; Lipoprotein(a); Saxony (Germany)

Indexed keywords

ATORVASTATIN; BILE ACID SEQUESTRANT; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGE DISTRIBUTION; AGED; APHERESIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE PREDISPOSITION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GERMANY; HOMOZYGOTE; HUMAN; HYPERTENSION; LIPOPROTEIN APHERESIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK REDUCTION; SEX RATIO; UNIVERSITY HOSPITAL;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD COMPONENT REMOVAL; CARDIOVASCULAR DISEASES; FEMALE; GERMANY; HUMANS; HYPERLIPOPROTEINEMIAS; LIPOPROTEINS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872839865     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2012.10.003     Document Type: Article

References (16)

1. Schettler V., Neumann C.L., Hulpke-Wette M., Hagenah G.C., Schulz E.G., Wieland E. Current view: indications for extracorporeal lipid apheresis treatment. Clin Res Cardiol Suppl 2012, 7(Suppl 1):15-19.
2. Heigl F., Hettich R., Lotz N., et al. Indication and implementation of lipidapheresis, rheopheresis, or immunoadsorption (lessons learnt from Germany's largest apheresis center). Atheroscler Suppl 2009, 10(5):137-141.
3. Julius U., Tselmin S., Fischer S., Passauer J., Bornstein S.R. The Dresden Apheresis Center - experience with LDL apheresis and immunoadsorption. Atheroscler Suppl 2009, 10(5):12-16.
4. Julius U., Frind A., Tselmin S., Kopprasch S., Poberschin I., Siegert G. Comparison of different LDL apheresis methods. Expert Rev Cardiovasc Ther 2008, 6(5):629-639.
5. Drager L.J., Julius U., Kraenzle K., et al. DALI-the first human whole-blood low-density lipoprotein and lipoprotein(a) apheresis system in clinical use: procedure and clinical results. Eur J Clin Invest 1998, 28(12):994-1002.
6. Armstrong V.W., Schuff-Werner P., Eisenhauer T., Helmhold M., Stix M., Seidel D. Heparin extracorporeal LDL precipitation (HELP): an effective apheresis procedure for lowering Lp(a) levels. Chem Phys Lipids 1994, 67-68:315-321.
7. Seidel D. H.E.L.P. apheresis therapy in the treatment of severe hypercholesterolemia: 10 years of clinical experience. Artif Organs 1996, 20(4):303-310.
8. Julius U., Parhofer K.G., Heibges A., Kurz S., Klingel R., Geiss H.C. Dextran-sulfate-adsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid-apheresis - comparison of performance characteristics with DALI and lipidfiltration. J Clin Apher 2007, 22(4):215-223.
9. Klingel R., Mausfeld P., Fassbender C., Goehlen B. Lipidfiltration - safe and effective methodology to perform lipid-apheresis. Transfus Apher Sci 2004, 30(3):245-254.
10. Richter W.O., Jacob B.G., Ritter M.M., Suhler K., Vierneisel K., Schwandt P. Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism 1993, 42(7):888-894.
11. Julius U., Tselmin S., Fischer S., Passauer J., Tsourdi E., Bornstein S.R. Lipid apheresis after heart transplantation - the Dresden experience. Transplantationsmedizin 2010, 22:355-362.
12. Kroon A.A., van't Hof M.A., Demacker P.N., Stalenhoef A.F. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis 2000, 152(2):519-526.
13. Thompson G.R., Barbir M., Davies D., et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010, 208(2):317-321.
14. Bruckenberger E. Herzbericht 2010 2011, vol. 23. Hannover.
15. Julius U, Fischer S, Schatz U, Passauer J, Bornstein SR. Why an apheresis center should offer more than one lipoprotein apheresis method. Therapeutic Apheresis and Dialysis, doi:10.1111/j.1744-9987.2012.01129.x.
16. Stefanutti C., Julius U. Lipoprotein apheresis: state of the art and novelties. Atheroscler Suppl 2013, 14(1):19-27.